Goldline Pharmaceutical IPO Day 1: The preliminary public providing (IPO) of Goldline Pharmaceutical opened for subscription immediately, 12 Could, and can shut on Thursday, 14 Could. The SME IPO value band has been set within the vary of ₹ ₹41-43 per share.
The corporate goals to boost ₹11.61 crore from this difficulty, which is totally a contemporary difficulty of 0.27 crore shares with no provide on the market part.
The idea of allotment for the IPO is prone to be finalised on Could 15, 2026. Buyers who obtain shares are anticipated to see them credited to their demat accounts by Could 18, whereas candidates who don’t obtain allotment could get their refunds initiated the identical day. The corporate is tentatively scheduled to debut on the BSE SME platform on Could 19.
Goldline Pharmaceutical IPO GMP At the moment
Investor sentiment towards the IPO is powerful, because the SME IPO’s gray market premium (GMP) is ₹17 on 12 Could. This implies that the inventory was prone to debut at ₹60, a premium of 39.53% from the IPO value.
‘Gray market premium’ signifies traders’ readiness to pay greater than the problem value.
Goldline Pharmaceutical IPO subscription standing
The subscription for this SME IPO will begin at 10:00 am.
Goldline Pharmaceutical IPO Particulars
In line with the corporate, the funds raised via the general public difficulty will primarily be utilised to scale back current debt obligations, together with unsecured borrowings, time period loans and dealing capital liabilities. Part of the proceeds may also be used for basic company functions, with such utilisation capped at both 15% of the gross proceeds or ₹1,000 lakh, whichever is decrease.
Buyers can bid for no less than 3,000 shares in a single lot. On the higher finish of the worth band, retail traders might want to make investments a minimal of ₹2.58 lakh for six,000 shares.
Forward of the IPO opening, Goldline Pharmaceutical raised ₹3.15 crore from anchor traders. The anchor investor bidding course of was performed on Could 11, 2026.
Cumulative Capital Pvt. Ltd. is performing because the book-running lead supervisor for the problem, whereas Bigshare Providers Pvt. Ltd. has been appointed because the registrar. The market-making duties for the IPO might be dealt with by Nirman Share Brokers Pvt. Ltd..
About Goldline Pharmaceutical
Goldline Pharmaceutical sells its merchandise underneath the in-house “Goldline” model and operates throughout 5 totally different pharmaceutical classes. The corporate follows an asset-light enterprise technique, outsourcing manufacturing to third-party companions as an alternative of working its personal manufacturing amenities. The corporate presently works with 15 contract producers that produce medicines and healthcare merchandise.
For the reason that firm doesn’t personal any manufacturing unit, its operations are closely depending on exterior distributors for manufacturing and provide administration. Distribution of merchandise is dealt with via a community of eight distributors, with the corporate usually providing a credit score interval of as much as 60 days.
Goldline Pharmaceutical’s enterprise stays largely concentrated in western and central India, with Maharashtra and Madhya Pradesh collectively contributing greater than 70% of its general income.
On the monetary entrance, the corporate has posted regular progress in income over the previous few years. Income from operations elevated from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024, earlier than rising additional to ₹28.06 crore in FY2025. For the 9 months ended December 31, 2025, the corporate reported income of ₹21.41 crore.
The corporate additionally witnessed a robust enchancment in profitability through the interval underneath evaluation. Its revenue after tax (PAT) margin expanded sharply from 1.31% in FY2023 to 10.09% in FY2025.
Disclaimer: This story is for academic functions solely. Please seek the advice of with an funding advisor earlier than making any funding selections.
